Alnylam Pharmaceuticals, Inc. (ETR:DUL)
Germany
· Delayed Price · Currency is EUR 277.50
+1.15 (0.42%)
Mar 6, 2026, 12:44 PM CET
Alnylam Pharmaceuticals Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2016 |
| Revenue | 3,714 | 2,248 | 1,828 | 1,037 | 844.29 | Upgrade
|
| Revenue Growth (YoY) | 65.19% | 22.97% | 76.23% | 22.88% | 71.31% | Upgrade
|
| Cost of Revenue | 681.87 | 323.37 | 310.41 | 168.82 | 140.14 | Upgrade
|
| Gross Profit | 3,032 | 1,925 | 1,518 | 868.6 | 704.14 | Upgrade
|
| Selling, General & Admin | 1,211 | 975.53 | 795.65 | 770.66 | 620.64 | Upgrade
|
| Research & Development | 1,320 | 1,126 | 1,004 | 883.02 | 792.16 | Upgrade
|
| Operating Expenses | 2,530 | 2,102 | 1,800 | 1,654 | 1,413 | Upgrade
|
| Operating Income | 501.58 | -176.89 | -282.18 | -785.07 | -708.65 | Upgrade
|
| Interest Expense | -252.63 | -141.86 | -121.22 | -155.97 | -143.02 | Upgrade
|
| Interest & Investment Income | 111.47 | 121.99 | 95.56 | 24.81 | 1.58 | Upgrade
|
| Other Non Operating Income (Expenses) | -34.96 | -177.6 | -108.74 | -100.86 | -57.75 | Upgrade
|
| EBT Excluding Unusual Items | 325.46 | -374.35 | -416.57 | -1,017 | -907.84 | Upgrade
|
| Gain (Loss) on Sale of Investments | -2.31 | -3.02 | -16.94 | -33.31 | 55.7 | Upgrade
|
| Other Unusual Items | - | - | - | -76.59 | - | Upgrade
|
| Pretax Income | 323.15 | -377.38 | -433.52 | -1,127 | -852.14 | Upgrade
|
| Income Tax Expense | 9.41 | -99.22 | 6.73 | 4.16 | 0.68 | Upgrade
|
| Net Income | 313.75 | -278.16 | -440.24 | -1,131 | -852.82 | Upgrade
|
| Net Income to Common | 313.75 | -278.16 | -440.24 | -1,131 | -852.82 | Upgrade
|
| Shares Outstanding (Basic) | 131 | 128 | 125 | 122 | 118 | Upgrade
|
| Shares Outstanding (Diluted) | 135 | 128 | 125 | 122 | 118 | Upgrade
|
| Shares Change (YoY) | 5.51% | 2.20% | 2.64% | 2.73% | 3.01% | Upgrade
|
| EPS (Basic) | 2.39 | -2.18 | -3.52 | -9.30 | -7.20 | Upgrade
|
| EPS (Diluted) | 2.33 | -2.18 | -3.52 | -9.30 | -7.20 | Upgrade
|
| Free Cash Flow | 465.38 | -42.59 | 41.95 | -613.33 | -718.07 | Upgrade
|
| Free Cash Flow Per Share | 3.46 | -0.33 | 0.34 | -5.04 | -6.06 | Upgrade
|
| Gross Margin | 81.64% | 85.62% | 83.02% | 83.73% | 83.40% | Upgrade
|
| Operating Margin | 13.51% | -7.87% | -15.43% | -75.68% | -83.94% | Upgrade
|
| Profit Margin | 8.45% | -12.37% | -24.08% | -109.04% | -101.01% | Upgrade
|
| Free Cash Flow Margin | 12.53% | -1.89% | 2.29% | -59.12% | -85.05% | Upgrade
|
| EBITDA | 557.24 | -120.22 | -228.12 | -740.6 | -661.09 | Upgrade
|
| EBITDA Margin | 15.00% | -5.35% | -12.48% | -71.39% | -78.30% | Upgrade
|
| D&A For EBITDA | 55.66 | 56.67 | 54.05 | 44.47 | 47.57 | Upgrade
|
| EBIT | 501.58 | -176.89 | -282.18 | -785.07 | -708.65 | Upgrade
|
| EBIT Margin | 13.51% | -7.87% | -15.43% | -75.67% | -83.94% | Upgrade
|
| Effective Tax Rate | 2.91% | - | - | - | - | Upgrade
|
| Revenue as Reported | 3,714 | 2,248 | 1,828 | 1,037 | 844.29 | Upgrade
|
| Advertising Expenses | 36 | 29.7 | 12.4 | 11.7 | - | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.